Culturally Tailored Educational Video to Promote Lung Cancer Screening in Vulnerable Communities

February 12, 2026 updated by: Thomas Jefferson University

Breathe Easier, Philadelphia! Engaging Vulnerable Communities for Innovative Lung Cancer Care

This clinical trial evaluates the impact of a culturally tailored educational video on the perceptions of lung cancer and lung cancer screening in vulnerable communities. Lung cancer is the most common cancer type. African-American communities have a higher rate than any other racial or ethnic group in the United States and accounts for the highest number of deaths among African-Americans. Lung cancer is in the top three causes of cancer death among Asian men and women. Research has shown that low-income, minority and immigrant individuals may be under resourced to make decisions about prevention programs and early detection measures for lung cancer. A culturally tailored educational video may be an effective method to help people learn about lung cancer, susceptibility toward lung cancer and lung cancer screening. This may increase lung cancer screening in vulnerable communities.

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Detailed Description

PRIMARY OBJECTIVES:

I. To understand barriers and opportunities for engaging three culturally distinct populations in lung cancer screening.

II. To develop three culturally tailored educational videos about lung cancer and the benefits of lung cancer screening.

III. To test the impact of the videos on susceptibility to lung cancer, knowledge of lung cancer screening, and intentions to undergo lung cancer screening in a diverse sample of at-risk individuals.

OUTLINE: Participants are assigned to 1 of 3 arms.

ARM I (AIM 1): Participants participate in a focus group over 1 hour in support of the development of a culturally tailored educational video on study.

ARM II (AIM 2): Participants watch a culturally tailored educational video over 3-5 minutes and then immediately undergo an interview in support of the refinement of a culturally tailored educational video on study.

ARM III (AIM 3): Participants watch a culturally tailored educational video over 3-5 minutes and complete a brief test pre- and post-video over 30 minutes on study.

Study Type

Interventional

Enrollment (Actual)

11

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19107
        • Thomas Jefferson University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • AIM 1: Participants must be African American, Korean, or Chinese adults who have either: a history of smoking, a history of lung cancer, or who have undergone lung cancer screening
  • AIM 2: Participants must be African American, Korean, or Chinese adults who have either: a history of smoking, a history of lung cancer, or who have undergone lung cancer screening
  • AIM 3: Those who are African American, Korean or Chinese, and are eligible for lung cancer screening, based on current screening guidelines: Current or former smokers who are between 50 and 80 years of age and who have smoked at least one pack a day for 20 years or two packs a day for 10 years

Exclusion Criteria:

  • AIM 1: Those excluded from participating include children; those who are not members of the African American, Chinese, or Korean community; those who do not have one of the following: a history of smoking, a history of lung cancer, or have undergone lung cancer screening
  • AIM 2: Those excluded from participating include children; those who are not members of the African American, Chinese, or Korean community; those who do not have one of the following: a history of smoking, a history of lung cancer, or have undergone lung cancer screening
  • AIM 3: Those excluded from participating include children; those who are not members of the African American, Chinese, or Korean community; those who do not have a history of smoking; those who have been diagnosed with lung cancer; those who have undergone lung cancer screening in the past

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Screening
  • Allocation: Non-Randomized
  • Interventional Model: Sequential Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Arm I (Aim 1) (focus group)
Participants participate in a focus group over 1 hour in support of the development of a culturally tailored educational video on study.
Procedure: Discussion
Participate in focus groups
Other Names:
  • Discuss
Experimental: Arm II (Aim 2) (video, interview)
Participants watch a culturally tailored educational video over 3-5 minutes and then immediately undergo an interview in support of the refinement of a culturally tailored educational video on study.
Other: Interview
Undergo interview
Other: Media Intervention
Watch culturally appropriate video
Experimental: Arm III (Aim 3) (video, test)
Participants watch a culturally tailored educational video over 3-5 minutes and complete a brief test pre- and post-video over 30 minutes on study.
Other: Media Intervention
Watch culturally appropriate video
Other: Test
Complete test

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To understand barriers and opportunities for engaging three culturally distinct populations in lung cancer screening.
Time Frame: From baseline to endpoint, up to 1 year
Participants will be asked about their awareness of lung cancer screening, known or perceived barriers to screening, and potential opportunities or initiatives that could increase lung cancer screening rates in their community. Discussions will be audio recorded, transcribed by a professional transcription company, and analyzed by the study team using qualitative research methods.
From baseline to endpoint, up to 1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To develop three culturally tailored educational videos about lung cancer and the benefits of lung cancer screening
Time Frame: From baseline to endpoint, up to 1 year
Ethnic cultural or other differences will be assessed and highlighted within each group, based on results from the focus groups. The beta versions of each video will be pre-tested among a small sample of individuals in each target population to refine and confirm the approach.
From baseline to endpoint, up to 1 year
To test the impact of the videos on susceptibility to lung cancer, knowledge of lung cancer screening, and intentions to undergo lung cancer screening in a diverse sample of at-risk individuals.
Time Frame: From baseline to endpoint, up to 1 year

First, participants will complete a brief pre-test measuring their susceptibility to lung cancer, their knowledge about lung cancer screening, their intentions to undergo lung cancer screening, and sociodemographic characteristics. Next, they will watch the video that was designed for their culture. Lastly, they will complete a post-test that includes the same measures as the pre-test, plus some additional metrics on the quality and satisfaction with the video.

The statistical analyses will focus on describing the sociodemographic characteristics, health behaviors, and health history of participants and testing their pre-post responses for the effects of the video intervention to address Aim 3. Descriptive statistics for continuous or ordinal (e.g., Likert) scaled study variables will include means with standard deviations (or medians with first and third quartiles for skewed data) and for discrete study variables will include frequency counts with percentages.
From baseline to endpoint, up to 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Thomas Jefferson University

Investigators

  • Principal Investigator: Amy R Leader, DrPH, MPH, Thomas Jefferson University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2023

Primary Completion (Actual)

February 19, 2025

Study Completion (Actual)

February 19, 2025

Study Registration Dates

First Submitted

August 18, 2023

First Submitted That Met QC Criteria

August 18, 2023

First Posted (Actual)

August 24, 2023

Study Record Updates

Last Update Posted (Actual)

February 17, 2026

Last Update Submitted That Met QC Criteria

February 12, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • iRISID-2022-1320
  • JT 25584 (Other Identifier: JeffTrial Number)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lung Carcinoma

Clinical Trials on Interview

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Philippines

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe